MedTrace Logo

Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine

NCT01978496 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1334

Last updated 2021-01-28

No results posted yet for this study

Summary

To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.

Conditions

  • Migraine With or Without Aura

Interventions

DRUG

Placebo

matching placebo

DRUG

Eletriptan 20 mg

20mg oral

DRUG

Eletriptan 40 mg

40mg oral

DRUG

Eletriptan 80 mg

80mg oral

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-07-31
Primary Completion
1997-12-31
Completion
1997-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01978496 on ClinicalTrials.gov